Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 4/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | DGKA | P23743 | 1/20 | 0.30 |
| ▸ | DGKZ | Q13574 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133764 | 1.00 | HRH3 (0.35) | HRH3XIAPBIRC2CHRM4KDM4E | |
| SCHEMBL4102926 | 1.00 | HRH3 (0.35) | HRH3XIAPBIRC2CHRM4KDM4E | |
| SCHEMBL4982738 | 0.86 | HRH3 (0.38) | HRH3XIAPBIRC2CACNA2D1OPRM1 | |
| SCHEMBL4107027 | 0.86 | HRH3 (0.38) | HRH3XIAPBIRC2CACNA2D1OPRM1 | |
| SCHEMBL4100180 | 0.86 | HRH3 (0.38) | HRH3XIAPBIRC2CACNA2D1OPRM1 | |
| SCHEMBL4093102 | 0.85 | HRH3 (0.39) | HRH3XIAPBIRC2CACNA2D1OPRM1 | |
| SCHEMBL4094531 | 0.85 | HRH3 (0.39) | HRH3XIAPBIRC2CACNA2D1OPRM1 | |
| SCHEMBL4099431 | 0.81 | HRH3 (0.34) | HRH3XIAPBIRC2 | |
| SCHEMBL5133237 | 0.81 | HRH3 (0.34) | HRH3XIAPBIRC2 | |
| SCHEMBL4097155 | 0.81 | HRH3 (0.34) | HRH3XIAPBIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | HRH3 2328/4885XIAP 3112/4885BIRC2 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.